



TuBerculosis Vaccine Initiative

Symposium

“Latest progress on TB biomarkers and TB vaccines”

Wednesday afternoon 1st February & Thursday morning 2nd February 2017

| Programme | Wednesday afternoon 1st February |
|------------------|---|
| 14.30 – 14.40 | Opening and Welcome – Nick Drager, Executive Director TBVI |
| | Session 1 TB Biomarkers: from discovery to clinical development <i>Moderator: Tom Ottenhoff (Leiden University Medical Center, Netherlands)</i> |
| 14.40 – 15.05 | TB Biomarker discovery: big data & bioinformatics - Helen Fletcher (London School of Hygiene & Tropical Medicine, United Kingdom) |
| 15.05 – 15.30 | TB Biomarker discovery: functional TB Biomarker assays, a progress report - Simone Joosten (Leiden University Medical Center, Netherlands) / Helen McShane (University of Oxford, United Kingdom) |
| 15.30 – 15.55 | Clinical development and validation of proteomic TB Biomarker assays - Gerhard Walzl (Stellenbosch University, South Africa) |
| 15.55 – 16.25 | <i>Coffee break / snack</i> |
| 16.25 – 16.50 | Human challenge models for Tuberculosis - Brian Robertson (Imperial College London, United Kingdom) |

16.50 – 17.20 Panel discussion on TB Biomarkers and human challenge models:
*Facilitator: **Hazel Dockrell** (LSHTM, United Kingdom)*
Stefan Kaufmann (MPIIB, Germany); **Tom Scriba**, (Univ. Capetown, South Africa);
Brian Robertson, (Imperial, United Kingdom). **Jaqui Shea**, (Aeras, US)

18.30 – 19.30 Reception (Eurotel)

Programme Thursday 2nd February 2017 (morning)

Session 2

TB vaccine R&D a strategic update

Moderator: Nick Drager (TBVI)

08.30 – 8.45 EC perspective – **Hannu Laang** (EC, Belgium)

08.45 – 09.00 WHO perspective - **Christian Lienhardt/ Martin Friede** (WHO, Switzerland)

09.00 – 09.15 Stop TB partnership working group on vaccines - **David Lewinsohn** (Oregon Health & Science University, United States)

Session 3

Preventive and therapeutic TB vaccination to prevent AMR, treat AMR; and possibly shorten TB treatment

Moderator: Jan Poolman (Janssen Vaccines & Prevention B.V, Netherlands)

09.15 – 09.40 Therapeutic TB vaccines: shortening TB treatment & treating DR-TB? –
Mark Hatherill, (SA Tuberculosis Vaccine Initiative, South Africa)

09.40 – 10.05 Immunological basis for therapeutic TB vaccines: mission (im)possible? - **Andrea Cooper**, (University of Leicester, United Kingdom)

10.05 – 10.20 MDR-TB and TB vaccines – **Martin Friede / Christian Lienhardt** (WHO, Switzerland)

10.20 – 10.45 Future drugs and treatment regimens for (DR)TB and a discussion on the role of therapeutic vaccines - **Mel Spigelman** (TB alliance, United States)

- 10.45 – 11.15 Panel discussion:
Facilitator: **Jan Poolman** (*Janssen Vaccines & Prevention B.V., Netherlands*)
Geneviève Inchauspé (Transgene, France); **Mark Hatherill** (SATVI, South Africa);
Peter Andersen (SSI, Denmark); **Prasad Kulkarni** (Serum Institute, India); **Mel Spiegelman** (TB alliance, United States)
- 11.15 – 11.45 *Coffee break*
- Session 4**
Updates on Vaccine Candidates & Clinical Development Strategies
Chairs: *Jacqui Shea (Aeras, United States) & Gerald Voss (TBVI, Netherlands)*
- 11.45 – 11.55 MTBVAC - **Carlos Martin** (University of Zaragoza, Spain);
- 11.55 – 12.05 VPM1002 - **Leander Grode** (Vakzine Projekt Management, Germany);
- 12.05 – 12.15 GSK TB vaccine candidates – **Olivier Van Der Meer** (GlaxoSmithKline, Belgium)
- 12.15 – 12.25 SSI vaccines - **Peter Andersen** (SSI, Denmark);
- 12.25 – 12.35 Virally vectored vaccines - **Helen McShane** (University of Oxford, United Kingdom)
- 12.35 – 12.45 IDRI vaccines – **Tracey Day** (Infectious Disease Research Institute, United States)
- 12.45 – 12.55 RUTI vaccine – **Pere-Joan Cardona** (Archivel Farma S.L. Spain)
- 13.00 – 14.00 *Buffet Lunch (restaurant Eurotel)*

TBVI Young Scientist Awards

In recognition of outstanding contributions in the field of TB vaccines R&D, TBVI will give **two 'TBVI Young Scientist Awards'**. The prizes are supported by a grant from GSK. Each prize consists of a scholarship (covering the conference fee and the travel and accommodation expenses) to attend one relevant scientific conference/symposium/training course.

The applicant should currently work in academia or a public or non-profit organization in the TBVI Network.

For more information about eligibility and selection criteria and how to apply for the award, please go to the webpage: <http://www.tbvi.eu/news-events/news/> or write to: info@tbvi.eu

The deadline for submission of applications is: **Friday, 10th of March 2017.**

Eurotel Victoria

Les Diablerets
Fam. Stéphane et Alexandra Wartner
Chemin du Vernex
1865 Les Diablerets
Switzerland
Phone: +41 24 492 37 21

Accommodation should be arranged via registration on website TBVI: www.tbvi.eu/subscription

Contact person TBVI:

Cora Agterdenbosch,
TBVI
Runderweg 6
8219 PK Lelystad
The Netherlands
Phone: +31 320 277550
e-mail: cora.agterdenbosch@tbvi.eu

Transportation:

Trains from/to Geneva Airport, change at Aigle.
120 minutes, schedules on <http://www.sbb.ch>